Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Neoadjuvant Chemotherapy for the Treatment of Patients With Bladder Cancer
July 27th 2015Alexander Kutikov, MD, FACS, attending surgeon, Urologic Oncology, associate professor, Urologic Oncology, Fox Chase Cancer Center, discusses neoadjuvant chemotherapy for the treatment of patients with bladder cancer.
Watch
Advantages of Using Y-90 for the First-Line Treatment of Patients With Liver Metastases from mCRC
July 24th 2015Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).
Watch
Study of Vemurafenib Combined With a MEK Inhibitor
July 23rd 2015Anna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the study of vemurafenib combined with a MEK inhibitor.
Watch
Patient Selection for Premenopausal Endocrine Therapy
July 23rd 2015Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses patient selection for premenopausal endocrine therapy.
Watch
Challenges Medical Oncologists Will Face Due To Health Care Reform
July 22nd 2015Debra Patt, MD, MPH, MBA, medical oncologist, director of Public Policy, Texas Oncology, director of Health Care Informatics, McKesson Specialty Health and The US Oncology Network, discusses the challenges that medical oncologists will face due to health care reform.
Watch
Treatment of Patients With HPV Associated Locally Advanced Oropharynx Cancer
July 20th 2015Barbara A. Burtness, MD, professor of medicine, clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses the treatment of patients with HPV associated locally advanced oropharynx cancer.
Watch
Adverse Effects of Anastrozole in Patients With DCIS
July 17th 2015Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).
Watch
Adverse Events of Nivolumab in Patients With Advanced, Non-Squamous NSCLC
July 17th 2015Mark A. Socinski, MD, professor, Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, University of Pittsburgh, discusses the adverse events, as well as the overall significance, of nivolumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Watch
A Study on Two Adjuvant Trials in Patients With Stage III Colon Cancer
July 16th 2015Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Cancer Center, Mayo Clinic discusses a study on two adjuvant trials in patients with stage III colon cancer.
Watch
Novel Agents in Breast Cancer and Monoclonal Antibodies
July 15th 2015Howard A. “Skip†Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Watch
Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric Cancer
July 13th 2015Yung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.
Watch
Testing and Treatment for Hepatitis C in Patients With HCC
July 13th 2015Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.
Watch
Safety and PK Results From an Ongoing Phase I-II Study of ONA in Patients With PR-Expressing Cancers
July 10th 2015Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.
Watch
Effects of SIRT and Bevacizumab on Extrahepatic CRC Metastases
July 9th 2015Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.
Watch
RAVD of Radiotherapy Using Induction Chemotherapy in LA-HNSCC
July 8th 2015Victoria M. Villaflor, MD, medical oncologist, associate professor, University of Chicago Medicine, discusses response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).
Watch
Nivolumab Compared to Docetaxel in Patients With NSCLC
July 8th 2015Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).
Watch
Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy Use
July 7th 2015James Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.
Watch
Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC
July 7th 2015Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).
Watch
Daratumumab for the Treatment of Patients With Multiple Myeloma
July 6th 2015Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.
Watch
Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer
July 2nd 2015Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Watch
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast Cancer
July 1st 2015Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.
Watch